June 18, 2014
This article was reported by TechTimes.
TechTimes reported that the U.S. Food and Drug Administration (FDA) has granted priority review for Illinois-based drug manufacturer AbbVie's experimental all-oral regimen for treating adults infected with hepatitis C virus (HCV). The drug's application under priority review means that FDA must evaluate the safety and effectiveness of the AbbVie regimen within six months before letting the manufacturer know whether they may take the product to market. FDA first granted breakthrough therapy designation to the manufacturer's investigational treatment for chronic genotype 1 HCV in May 2013 when preliminary clinical evidence showed that the regimen led to better results than conventionally accepted treatments. AbbVie's new regimen consists of an antiviral called ritonavir and a protease inhibitor called ABT-450, combined with an NS5A inhibitor called ombitasvir and the polymerase inhibitor dasabuvir. When taken together, these mechanisms are powerful enough to stop HCV.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|